Search - tctmd.com

Displaying 401 - 420 of 684

Sort: Relevancy | Date

Presentation TCT 2018

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Stephan Windecker

September 23, 2018

Presentation TCT 2018

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Giuseppe Biondi-Zoccai

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Kurt Huber

September 23, 2018

Presentation TCT 2018

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Presenter: Deepak L. Bhatt, Gregg W. Stone, Otavio Berwanger, Peter Juni, Sanjay Kaul, Roxana Mehran, E. Magnus Ohman, Stuart J. Pocock, Giulio Stefanini

September 23, 2018

Presentation TCT 2018

Are Randomized Trials Feasible for Percutaneous Mechanical Support Devices?

Presenter: Nicole Ibrahim, David E. Kandzari, Holger Thiele

September 23, 2018

Presentation TCT 2018

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Presenter: Peter Juni, Robert W. Yeh, Roxana Mehran

September 23, 2018

Presentation TCT 2018

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Presenter: Peter Juni, Robert W. Yeh, David J. Cohen

September 23, 2018

Presentation TCT 2018

Most Frequent Errors I See in the Analysis and Interpretation of Trials

Presenter: Peter Juni, Robert W. Yeh

September 23, 2018

Presentation TCT 2018

How to Make Trials Larger, Simpler and Less Expensive

Presenter: Peter Juni, Robert W. Yeh, Matthew T. Roe

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, William F. Fearon

September 23, 2018

Presentation TCT 2018

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Bernard J. Gersh

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

Presenter: Ajay J. Kirtane, Stuart J. Pocock

September 23, 2018

Presentation TCT 2018

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Presenter: Ajay J. Kirtane, Stuart J. Pocock, Rasha Al-Lamee

September 23, 2018

Presentation TCT 2018

Patient Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Debbe McCall

September 23, 2018

Presentation TCT 2018

FDA Perspectives on Sham-Controlled Trials

Presenter: Kenneth J. Cavanaugh Jr, Roxana Mehran, Hiren Mistry

September 23, 2018

Presentation TCT 2018

CMS Perspectives

Presenter: Lori M Ashby

September 22, 2018

Presentation TCT 2018

Clinician Perspectives

Presenter: Megan Coylewright

September 22, 2018

Presentation TCT 2018

Patient-Centered Engagement in Trials: Case Example - ADAPTABLE

Presenter: John C Laschinger, J. Dawn Abbott, Lori M Ashby, Robert A. Byrne, David A. Cox, Mona Fiuzat, Christopher O'Connor, John A. Spertus, Susan Strong

September 22, 2018

Presentation TCT 2018

FDAs Patient Engagement Initiatives: How FDA Can Incorporate Patient Centered and Patient Reported Outcomes in Regulatory Decision-Making

Presenter: John C Laschinger

September 22, 2018

Presentation TCT 2018

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

Presenter: Marek Grygier

September 22, 2018

Advertisement

ESC 2018 Late Breaking Trial #2 - MitraFR: What I Liked and What I Question

ESC 2018 Late Breaking Trial #1 Global Leaders: What I Liked and What I Question

ACC 2018 Late Breaking Trial #2- COMPASS : What I Liked and What I Question

ACC 2018 Late Breaking Trial #1 - ODYSSEY Outcomes: What I Liked and What I Question

Are Randomized Trials Feasible for Percutaneous Mechanical Support Devices?

Stent Trials in High Bleeding Risk Patients: What is the Level of Evidence We Need?

Non-Inferiority Trials Gone Wrong: Examples From the Recent Literature

Most Frequent Errors I See in the Analysis and Interpretation of Trials

How to Make Trials Larger, Simpler and Less Expensive

Sham Controlled Trials for Devices Are Unethical, Unfeasible, and Unnecessary!

Sham Controlled Trials Should Be the New Gold Standard for Device Trials!

ORBITA in the Spotlight: How I Would Have Done the Trial Differently

ORBITA in the Spotlight: How I Interpret ORBITA as an Interventional Cardiologist

Patient Perspectives on Sham-Controlled Trials

FDA Perspectives on Sham-Controlled Trials

CMS Perspectives

Clinician Perspectives

Patient-Centered Engagement in Trials: Case Example - ADAPTABLE

FDAs Patient Engagement Initiatives: How FDA Can Incorporate Patient Centered and Patient Reported Outcomes in Regulatory Decision-Making

The Current Target Population for LAAC Closure Based on the Results of Clinical Trials in Europe

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content